Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non‐metastatic breast cancer

AIMS: Trastuzumab, an antibody binding to epidermal growth factor receptor‐2 (HER2), has been approved to treat HER2‐positive breast cancer in different settings. This study aimed at evaluating the influence of tumour size on trastuzumab pharmacokinetics (PK) in non‐metastatic breast cancer patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Bernadou, Guillemette, Campone, Mario, Merlin, Jean‐Louis, Gouilleux‐Gruart, Valérie, Bachelot, Thomas, Lokiec, François, Rezai, Keyvan, Arnedos, Monica, Diéras, Véronique, Jimenez, Marta, Paintaud, Gilles, Ternant, David
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Pharmacokinetics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4834606/
https://ncbi.nlm.nih.gov/pubmed/26714164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12875
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados